Ads
related to: lymphoma tumor markersassistantmagic.com has been visited by 100K+ users in the past month
explorepanel.com has been visited by 10K+ users in the past month
assistantking.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
A tumor marker is a biomarker that can be used to indicate the presence of cancer or the behavior of cancers ... lymphoma, leukemia, lung cancer, prostate cancer [17]
Lymphoma is the most common form of hematological malignancy, or "blood cancer", in the developed world. Taken together, lymphomas represent 5.3% of all cancers (excluding simple basal cell and squamous cell skin cancers) in the United States and 55.6% of all blood cancers.
The tumor cells in Burkitt lymphoma generally strongly express markers of B cell differentiation (CD20, CD22, CD19), as well as CD10 and BCL6. The tumor cells are generally negative for BCL2 and TdT. The high mitotic activity of Burkitt lymphoma is confirmed by nearly 100% of the cells staining positive for Ki67. [23]
CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors. [8] CD30 and CD15 are also expressed on Reed-Sternberg cells typical for Hodgkin's lymphoma. [9]
The neoplastic cells strongly express CD30 (100% of cases), CD2 (78%), CD4 (54–90% of cases), cytotoxicity marker proteins, and various other marker proteins that help distinguish it from other ALCL, cutaneous T-cell lymphomas, and cancers. While these cells typically are ALK-negative, they do express ALK-containing fusion proteins in rare cases.
A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule." [18] In cancer research and medicine, biomarkers are used in three primary ways: [19] To help diagnose conditions, as in the case of identifying early stage cancers (diagnostic)
Testing for high levels of lactate dehydrogenase in patients with non-Hodgkin's lymphoma is useful because it is released when body tissues break down for any reason. While it cannot be used as a sole means of diagnosing non-Hodgkin's lymphoma, it is a marker for tracking tumor burden in those diagnosed by other means.
The use of rituximab has been established for the treatment of B-cell–derived hematologic malignancies, including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). [ 7 ] In addition to cure-directed treatment, people can benefit from self-care to manage symptoms.
Ads
related to: lymphoma tumor markersassistantmagic.com has been visited by 100K+ users in the past month
explorepanel.com has been visited by 10K+ users in the past month
assistantking.com has been visited by 10K+ users in the past month